For about two decades, the medication side of addiction treatment barely moved. Three approved drugs for opioid use disorder, a thick stack of rules about who could prescribe them, daily lines outside methadone clinics. The last three years broke that pattern in ways most people, including plenty of clinicians, haven’t caught up on yet.
The Shot That Replaced the Daily Dose
Extended-release buprenorphine injections quietly changed the adherence math. Sublocade delivers a month of medication in one subcutaneous shot. Brixadi, approved more recently, comes in weekly and monthly formulations, which gives prescribers room to start someone on a shorter interval and stretch it out later.
The evidence has held up. Monthly injectable buprenorphine beats placebo injection and performs about as well as daily sublingual buprenorphine-naloxone. The VA’s BRAVE trial followed roughly 950 veterans for a full year comparing the two.
The practical difference isn’t clinical elegance. It’s that there’s no bottle at home to lose, no dose skipped because work ran long, no withdrawal creeping in on day two of a bad week.
Rules That Finally Bent
Methadone regulation got its first substantive rewrite in more than 20 years when SAMHSA overhauled 42 CFR Part 8 in February 2024. Take-home doses now rest on the treating clinician’s judgment instead of a rigid time-in-treatment checklist. Patients can qualify at intake. Nurse practitioners and physician assistants can order these medications. Federal data showed the pandemic-era take-home flexibility did not increase methadone deaths, and diversion stayed low, which is what made the change defensible.
Telehealth shifted too. DEA and HHS finalized a permanent pathway for starting buprenorphine through an audio-visual telemedicine visit, and broader controlled-substance telehealth flexibilities run through the end of 2026 while permanent rules get written. For rural parts of coastal South Carolina, that has measurably shrunk the number of counties with no reachable treatment at all.
Starting Buprenorphine When Fentanyl Is Involved
This is where practice changed most and gets discussed least. Fentanyl is lipophilic, so it accumulates in fat tissue and clears slowly and unpredictably. The old protocol, wait for moderate withdrawal and then give a standard first dose, now carries a real risk of precipitated withdrawal. That experience is miserable enough to send people straight back to using.
Two workarounds have become common. Low-dose initiation layers in very small buprenorphine doses over several days while the person is still using, sidestepping the withdrawal cliff. High-dose initiation, usually in an emergency department, does the opposite and pushes past the risk window fast. Maintenance doses above the old 16 mg reference point are also more accepted now.
Alcohol has real options too
Naltrexone, as a daily pill or a monthly injection, blunts the reward from drinking. Acamprosate helps with the restlessness and sleep disruption that drive relapse weeks after the last drink. Topiramate and gabapentin get used off label with reasonable trial support behind them. Most people with alcohol use disorder are never offered any of it, which is a systems failure rather than a science problem.
The GLP-1 Question
Semaglutide keeps turning up in addiction research. A randomized trial found low-dose semaglutide reduced lab-measured alcohol intake and weekly craving versus placebo. Large observational datasets link GLP-1 exposure to fewer alcohol-related hospitalizations and fewer opioid overdose events. But one published trial came back null overall, and phase 3 work is still running. Promising signal. Not a treatment yet.
Questions People Actually Ask
Isn’t this just trading one addiction for another?
No, and the distinction matters. Physical dependence on a stable prescribed medication is not the same thing as compulsive use that wrecks your life. At therapeutic doses, buprenorphine and methadone do not produce a high in someone who is tolerant. Both cut overdose death risk by roughly half.
How long do people stay on medication?
There’s no fixed number, but short courses have poor outcomes. Relapse rates climb sharply when people taper off inside the first year. Plenty stay on medication for years, some indefinitely, the same way someone manages blood pressure.
Do I have to show up somewhere every single day?
Often no. Between telehealth initiation, long-acting injections, and the newer take-home rules, a plan can fit around a job and a family instead of the other way around.
Where That Leaves You
If you or someone in your house is weighing options, the useful question isn’t whether medication works. That part is settled. The question is which one, at what dose, delivered how, and with what support wrapped around it. Programs offering medication assisted treatment in Bluffton and the surrounding Lowcountry now have tools that didn’t exist five years ago, and a clinical team like the one at Southern Sky Recovery can walk you through what fits. Ask specifically about injectable options and how they handle fentanyl-involved starts. The answers will tell you plenty.
